Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917929 | 0.80 | PNMT (0.34) | PNMTMEN1TSHRCYP2C19RAB9A | |
| SCHEMBL18425606 | 0.71 | — | — | |
| SCHEMBL13983617 | 0.68 | PNMT (0.36) | PNMTMEN1TSHRCYP2C19RAB9A | |
| SCHEMBL18423761 | 0.68 | MEN1 (0.41) | PNMTMEN1TSHRCYP2C19RAB9A | |
| SCHEMBL24591053 | 0.67 | PNMT (0.35) | PNMTMEN1TSHRCYP2C19RAB9A | |
| SCHEMBL13299219 | 0.67 | DRD2 (0.32) | PNMT | |
| SCHEMBL17339865 | 0.65 | PNMT (0.55) | PNMTMEN1TSHRCYP2C19RAB9A | |
| SCHEMBL15980346 | 0.65 | PNMT (0.37) | PNMT | |
| SCHEMBL24595484 | 0.63 | — | — | |
| SCHEMBL14642176 | 0.63 | MEN1 (0.30) | MEN1TSHRCYP2C19RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4108729-A1 | INK COMPOSITION AND METHOD FOR PRODUCING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-12-28 | — | — | EP | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | PNMT 2316/4885MEN1 474/4885TSHR 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.